As of 2025-03-21, the EV/EBITDA ratio of Rapid Dose Therapeutics Corp (DOSE.CN) is -7.35. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. DOSE.CN's latest enterprise value is 26.91 mil CAD. DOSE.CN's TTM EBITDA according to its financial statements is -3.66 mil CAD. Dividing these 2 quantities gives us the above DOSE.CN EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 7.3x - 10.9x | 9.1x |
| Forward P/E multiples | 8.8x - 13.3x | 11.0x |
| Fair Price | (0.27) - (0.33) | (0.30) |
| Upside | -240.8% - -271.8% | -259.2% |
| Date | EV/EBITDA |
| 2025-03-18 | -7.35 |
| 2025-03-17 | -7.00 |
| 2025-03-14 | -7.35 |
| 2025-03-13 | -7.00 |
| 2025-03-12 | -7.00 |
| 2025-03-11 | -7.35 |
| 2025-03-10 | -7.00 |
| 2025-03-07 | -7.53 |
| 2025-03-06 | -7.53 |
| 2025-03-05 | -7.35 |
| 2025-03-04 | -7.70 |
| 2025-03-03 | -9.12 |
| 2025-02-28 | -6.64 |
| 2025-02-27 | -6.29 |
| 2025-02-26 | -7.35 |
| 2025-02-25 | -7.35 |
| 2025-02-24 | -7.00 |
| 2025-02-20 | -7.35 |
| 2025-02-19 | -7.35 |
| 2025-02-18 | -7.35 |
| 2025-02-14 | -7.17 |
| 2025-02-13 | -7.17 |
| 2025-02-11 | -7.70 |
| 2025-02-10 | -7.88 |
| 2025-02-07 | -7.70 |
| 2025-02-05 | -7.35 |
| 2025-02-04 | -7.70 |
| 2025-02-03 | -8.23 |
| 2025-01-31 | -7.35 |
| 2025-01-30 | -7.70 |
| 2025-01-29 | -7.70 |
| 2025-01-28 | -8.23 |
| 2025-01-27 | -7.88 |
| 2025-01-24 | -7.88 |
| 2025-01-23 | -7.70 |
| 2025-01-22 | -7.70 |
| 2025-01-21 | -7.35 |
| 2025-01-20 | -7.53 |
| 2025-01-17 | -7.70 |
| 2025-01-16 | -7.70 |
| 2025-01-15 | -8.41 |
| 2025-01-14 | -8.06 |
| 2025-01-13 | -8.06 |
| 2025-01-10 | -8.59 |
| 2025-01-08 | -9.12 |
| 2025-01-07 | -8.59 |
| 2025-01-06 | -8.59 |
| 2025-01-03 | -9.12 |
| 2025-01-02 | -8.59 |
| 2024-12-31 | -8.41 |